Key Highlights

  • Faeth Therapeutics (NASDAQ:FTH) closed 42.5% lower on November 9, 2026, one of the steepest declines in the US market on a day when the S&P 500 rose about 2.4%.
  • Preliminary Phase 2 PIK-201 data showed a confirmed objective response rate of 33% for the PIKTOR and paclitaxel combination in 36 evaluable patients with advanced endometrial cancer.
  • Disease control reached 83%, median progression-free survival was 7.4 months, and patients with PIK3CA mutations responded at a rate of 44%.
  • Grade 3 or higher treatment-related neutropenia occurred in 26% of patients, while only two of 42 patients stopped treatment because of side effects.

What the Trial Showed

PIKTOR is an all-oral combination of serabelisib and sapanisertib, two drugs designed to block the PI3K, AKT and mTOR signalling pathway that drives growth in many tumours. In PIK-201, Faeth Therapeutics (NASDAQ:FTH) paired the regimen with paclitaxel in 42 patients with advanced endometrial cancer carrying mutations in that pathway. Every patient had already received a taxane, the median age was 64.5, and 48% had diabetes or prediabetes, a relevant detail because pathway inhibitors often raise blood sugar. With a data cut-off of October 23, 2026, 36 patients could be assessed for efficacy. The confirmed response rate was 33%, disease control was 83% and median progression-free survival was 7.4 months. Circulating tumour DNA fell early in 13 of 17 patients with samples. The company described the activity as supportive of further development in a heavily pretreated group.

Why the Market Reacted So Harshly

The scale of the fall suggests investors had priced in a stronger efficacy signal. A 33% confirmed response rate is respectable for a late-line population, but the comparison that matters is with paclitaxel alone and with other targeted options, and a single-arm study of 42 patients cannot settle that question. The company also said figures may change as scans are confirmed and patients remain on study, which leaves the headline number provisional. Pre-revenue developers with one lead asset tend to trade on binary readings of their first meaningful data set, and a result read as merely adequate can trigger heavy selling. The broader tape offered no shelter, as risk appetite flowed toward chipmakers and cyclicals rather than single-asset biotechs during the rebound on November 9, 2026.

Safety Profile and Key Risks

Tolerability was a relative positive. Treatment-related stomatitis affected 21% of patients and hyperglycaemia 12%, lower than many investors associate with this drug class, and there were no treatment-related deaths. Neutropenia of grade 3 or higher, at 26%, was the most frequent serious side effect and may be partly linked to paclitaxel. For holders of Faeth Therapeutics (NASDAQ:FTH), the main risks now are durability, since response duration has not yet been reported, the design of any registrational trial, and funding. The company has no product Revenue and losses have been widening, so future Capital raises are likely before any approval, and a lower share price makes such raises more dilutive. Updated data with mature follow-up, expected as more patients complete confirmatory scans, will be the next important test for the programme and for confidence in the wider pipeline.

Where Things Stand

Faeth Therapeutics lost 42.5% on November 9, 2026 because Phase 2 PIKTOR data, with a 33% confirmed response rate and 7.4 months of median progression-free survival, fell short of what the market appeared to expect. The safety profile was manageable and the PIK3CA subgroup looked stronger at 44%. Durability data, the path to a pivotal study and the funding plan are the issues to monitor from here.